The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InHofseth BioCare ASA (HBC) has released positive results from a head-to-head clinical trial for its patented OmeGo product. The study revealed that OmeGo increased the Omega 3 Index (O3I) by more than 70% over a 14-week period. Furthermore, the product demonstrated superior efficacy compared to a leading supplement brand in reducing key inflammatory markers, including hsCRP and TNFa. Analysts describe these findings as "paradigm-changing" for the efficacy of full-spectrum omega supplements. This clinical validation is expected to strengthen HBC's competitive position in the global health-science market. The bullish sentiment reflects the potential for increased market share and investor confidence following these robust medical findings.